Hostname: page-component-669899f699-g7b4s Total loading time: 0 Render date: 2025-05-01T13:35:47.092Z Has data issue: false hasContentIssue false
  • English
  • Français

Wnt/β-catenin signalling pathway in breast cancer cells and its effect on reversing tumour drug resistance by alkaloids extracted from traditional Chinese medicine

Part of: Cancer Research

Published online by Cambridge University Press:  19 June 2023

Xin-Lei Wu ,
Shen-Guo Lin ,
Yi-Wen Mao ,
Jun-Xian Wu ,
Chen-Da Hu ,
Rui Lv ,
Hong-Dou Zeng ,
Ming-Hao Zhang ,
Li-Zi Lin  and
Shan-Shan Ouyang
...Show all authors
Xin-Lei Wu
Affiliation:
Second College of Clinical Medical, Wenzhou Medical University, Wenzhou, China
Shen-Guo Lin
Affiliation:
Second College of Clinical Medical, Wenzhou Medical University, Wenzhou, China Department of Breast Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
Yi-Wen Mao
Affiliation:
Second College of Clinical Medical, Wenzhou Medical University, Wenzhou, China Department of Breast Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
Jun-Xian Wu
Affiliation:
Second College of Clinical Medical, Wenzhou Medical University, Wenzhou, China
Chen-Da Hu
Affiliation:
Second College of Clinical Medical, Wenzhou Medical University, Wenzhou, China Department of Breast Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
Rui Lv
Affiliation:
Second College of Clinical Medical, Wenzhou Medical University, Wenzhou, China Department of Breast Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
Hong-Dou Zeng
Affiliation:
Second College of Clinical Medical, Wenzhou Medical University, Wenzhou, China Department of Breast Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
Ming-Hao Zhang
Affiliation:
Second College of Clinical Medical, Wenzhou Medical University, Wenzhou, China Department of Breast Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
Li-Zi Lin
Affiliation:
Second College of Clinical Medical, Wenzhou Medical University, Wenzhou, China
Shan-Shan Ouyang
Affiliation:
Second College of Clinical Medical, Wenzhou Medical University, Wenzhou, China
Ya-Xin Zhao*
Affiliation:
Department of Breast Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
*
Corresponding author: Ya-Xin Zhao; Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Breast cancer is a high-risk disease with a high mortality rate among women. Chemotherapy plays an important role in the treatment of breast cancer. However, chemotherapy eventually results in tumours that are resistant to drugs. In recent years, many studies have revealed that the activation of Wnt/β-catenin signalling is crucial for the emergence and growth of breast tumours as well as the development of drug resistance. Additionally, drugs that target this pathway can reverse drug resistance in breast cancer therapy. Traditional Chinese medicine has the properties of multi-target and tenderness. Therefore, integrating traditional Chinese medicine and modern medicine into chemotherapy provides a new strategy for reversing the drug resistance of breast tumours. This paper mainly reviews the possible mechanism of Wnt/β-catenin in promoting the process of breast tumour drug resistance, and the progress of alkaloids extracted from traditional Chinese medicine in the targeting of this pathway in order to reverse the drug resistance of breast cancer.

Keywords

alkaloidsbreast cancerdrug resistancetraditional Chinese medicineWnt/β-catenin
Type
Review
Information
Expert Reviews in Molecular Medicine , Volume 25 , 2023 , e21
Check for updates
Copyright
Copyright © The Author(s), 2023. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

*

These authors contributed equally to this work.

References

Siegel, RL et al. (2021) Cancer statistics, 2021. CA: A Cancer Journal for Clinicians 71, 7–33.Google Scholar
Kashyap, D et al. (2022) Global increase in breast cancer incidence: risk factors and preventive measures. Biomed Research International 2022, 9605439.CrossRefGoogle ScholarPubMed
Dong, X et al. (2020) Exosomes and breast cancer drug resistance. Cell Death & Disease 11, 987.CrossRefGoogle ScholarPubMed
Koual, M et al. (2020) Environmental chemicals, breast cancer progression and drug resistance. Environmental Health: A Global Access Science Source 19, 117.CrossRefGoogle ScholarPubMed
Merikhian, P et al. (2021) Triple-negative breast cancer: understanding Wnt signaling in drug resistance. Cancer Cell International 21, 419.CrossRefGoogle ScholarPubMed
Bugter, JM et al. (2021) Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nature Reviews Cancer 21, 5–21.CrossRefGoogle ScholarPubMed
Xu, X et al. (2020) Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Molecular Cancer 19, 165.CrossRefGoogle ScholarPubMed
Nusse, R et al. (2017) Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell 169, 985–999.CrossRefGoogle ScholarPubMed
Zhang, Y et al. (2020) Targeting the Wnt/β-catenin signaling pathway in cancer. Journal of Hematology & Oncology 13, 165.CrossRefGoogle ScholarPubMed
Zhan, T et al. (2017) Wnt signaling in cancer. Oncogene 36, 1461–1473.CrossRefGoogle ScholarPubMed
Agostino, M et al. (2020) The structural biology of canonical Wnt signalling. Biochemical Society Transactions 48, 1765–1780.CrossRefGoogle ScholarPubMed
Katoh, M (2017) Canonical and non-canonical WNT signaling in cancer stem cells and their niches: cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). International Journal of Oncology 51, 1357–1369.CrossRefGoogle ScholarPubMed
Raut, D et al. (2022) The Wnt/β-catenin pathway in breast cancer therapy: a pre-clinical perspective of its targeting for clinical translation. Expert Review of Anticancer Therapy 22, 97–114.CrossRefGoogle ScholarPubMed
Shen, H et al. (2019) Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemotherapy-resistance by stabilizing β-catenin. Journal of Experimental & Clinical Cancer Research: CR 38, 243.CrossRefGoogle ScholarPubMed
Jia, D et al. (2017) An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells. Cell Death & Disease 8, e2932.CrossRefGoogle ScholarPubMed
Pan, Y et al. (2018) Therapeutic approaches targeting cancer stem cells. Journal of Cancer Research and Therapeutics 14, 1469–1475.Google ScholarPubMed
Palomeras, S et al. (2018) Targeting breast cancer stem cells to overcome treatment resistance. Molecules 23, 2193.CrossRefGoogle ScholarPubMed
Du, FY et al. (2019) Targeting cancer stem cells in drug discovery: current state and future perspectives. World Journal of Stem Cells 11, 398–420.CrossRefGoogle ScholarPubMed
Kakarala, M et al. (2010) Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Research and Treatment 122, 777–785.CrossRefGoogle ScholarPubMed
Song, K et al. (2021) Signaling pathways governing breast cancer stem cells behavior. Stem Cell Research & Therapy 12, 245.CrossRefGoogle ScholarPubMed
Liu, JH et al. (2021) MiR-526b-3p attenuates breast cancer stem cell properties and chemoresistance by targeting HIF-2α/Notch signaling. Frontiers in Oncology 11, 696269.CrossRefGoogle ScholarPubMed
Li, XS et al. (2014) ALDH1A1 overexpression is associated with the progression and prognosis in gastric cancer. BMC Cancer 14, 705.CrossRefGoogle ScholarPubMed
Lee, KM et al. (2017) MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metabolism 26, 633–647, e7.CrossRefGoogle ScholarPubMed
De Angelis, ML et al. (2019) Breast cancer stem cells as drivers of tumor chemoresistance, dormancy and relapse: new challenges and therapeutic opportunities. Cancers 11, 1569.CrossRefGoogle ScholarPubMed
Chang, CH et al. (2015) Mammary stem cells and tumor-initiating cells are more resistant to apoptosis and exhibit increased DNA repair activity in response to DNA damage. Stem Cell Reports 5, 378–391.CrossRefGoogle ScholarPubMed
Yin, S et al. (2017) Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells. PLoS ONE 12, e0183578.CrossRefGoogle ScholarPubMed
Ryu, WJ et al. (2020) Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer. Experimental and Molecular Medicine 52, 832–842.CrossRefGoogle ScholarPubMed
Li, X et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. Journal of the National Cancer Institute 100, 672–679.CrossRefGoogle ScholarPubMed
Klein, EA et al. (2008) Transcriptional regulation of the cyclin D1 gene at a glance. Journal of Cell Science 121, 3853–3857.CrossRefGoogle ScholarPubMed
Liu, Y et al. (2021) MYC dysfunction modulates stemness and tumorigenesis in breast cancer. International Journal of Biological Sciences 17, 178–187.CrossRefGoogle ScholarPubMed
Yang, B et al. (2021) Transmembrane protein TMEM119 facilitates the stemness of breast cancer cells by activating Wnt/β-catenin pathway. Bioengineered 12, 4856–4867.CrossRefGoogle ScholarPubMed
Liao, M et al. (2021) Autophagy blockade by Ai Du Qing formula promotes chemosensitivity of breast cancer stem cells via GRP78/β-catenin/ABCG2 axis. Frontiers in Pharmacology 12, 659297.CrossRefGoogle Scholar
Wang, C et al. (2020) Silencing of KIF3B suppresses breast cancer progression by regulating EMT and Wnt/β-catenin signaling. Frontiers in Oncology 10, 597464.CrossRefGoogle ScholarPubMed
Gooding, AJ et al. (2020) Epithelial-mesenchymal transition programs and cancer stem cell phenotypes: mediators of breast cancer therapy resistance. Molecular Cancer Research 18, 1257–1270.CrossRefGoogle ScholarPubMed
Pan, G et al. (2021) EMT-associated microRNAs and their roles in cancer stemness and drug resistance. Cancer Communications 41, 199–217.CrossRefGoogle ScholarPubMed
Shi, RZ et al. (2021) Epithelial cell adhesion molecule promotes breast cancer resistance protein-mediated multidrug resistance in breast cancer by inducing partial epithelial-mesenchymal transition. Cell Biology International 45, 1644–1653.CrossRefGoogle ScholarPubMed
Ye, X et al. (2015) Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 525, 256–260.CrossRefGoogle ScholarPubMed
Nakanishi, T et al. (2012) Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chinese Journal of Cancer 31, 73–99.CrossRefGoogle ScholarPubMed
Black, PC et al. (2011) Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. Journal of Urology 185, 693–700.CrossRefGoogle ScholarPubMed
Simanshu, DK et al. (2017) RAS proteins and their regulators in human disease. Cell 170, 17–33.CrossRefGoogle ScholarPubMed
McCubrey, JA et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta 1773, 1263–1284.CrossRefGoogle ScholarPubMed
Guerrero-Zotano, A et al. (2016) PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer and Metastasis Reviews 35, 515–524.CrossRefGoogle ScholarPubMed
Araki, K et al. (2018) Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer 25, 392–401.CrossRefGoogle ScholarPubMed
Janiszewska, M et al. (2021) The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+breast cancer. JCI Insight 6, e147617.Google ScholarPubMed
Husna, SMN et al. (2018) Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review. Therapeutic Advances in Medical Oncology 10, 1758835918808509.Google Scholar
Sobral-Leite, M et al. (2019) Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. Breast Cancer Research: BCR 21, 90.CrossRefGoogle ScholarPubMed
Dong, C et al. (2021) Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer. Frontiers in Pharmacology 12, 628690.CrossRefGoogle ScholarPubMed
Tzeng, HE et al. (2015) The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor. Oncotarget 6, 11061–11073.CrossRefGoogle ScholarPubMed
Jabbarzadeh Kaboli, P et al. (2020) Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer – a comprehensive review from chemotherapy to immunotherapy. Pharmacological Research 156, 104806.CrossRefGoogle ScholarPubMed
Kontomanolis, EN et al. (2018) The Notch pathway in breast cancer progression. TheScientificWorldJournal 2018, 2415489.CrossRefGoogle ScholarPubMed
Yuan, X et al. (2015) Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Letters 369, 20–27.CrossRefGoogle ScholarPubMed
Nandi, A et al. (2020) The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance. Genes & Development 34, 1422–1438.CrossRefGoogle ScholarPubMed
Saha, SK et al. (2019) Opposing regulation of cancer properties via KRT19-mediated differential modulation of Wnt/β-catenin/Notch signaling in breast and colon cancers. Cancers 11, 99.CrossRefGoogle ScholarPubMed
Zhang, J et al. (2016) NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling. Oncotarget 7, 61036–61053.CrossRefGoogle ScholarPubMed
Saha, SK et al. (2017) KRT19 directly interacts with β-catenin/RAC1 complex to regulate NUMB-dependent NOTCH signaling pathway and breast cancer properties. Oncogene 36, 332–349.CrossRefGoogle ScholarPubMed
Nasser, F et al. (2021) Dual targeting of Notch and Wnt/β-catenin pathways: potential approach in triple-negative breast cancer treatment. Naunyn-Schmiedeberg's Archives of Pharmacology 394, 481–490.CrossRefGoogle ScholarPubMed
Zhang, H et al. (2020) Complex roles of cAMP-PKA-CREB signaling in cancer. Experimental Hematology & Oncology 9, 32.CrossRefGoogle ScholarPubMed
Moody, SE et al. (2015) PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene 34, 2061–2071.CrossRefGoogle ScholarPubMed
Katoh, M et al. (2017) Molecular genetics and targeted therapy of WNT-related human diseases (review). International Journal of Molecular Medicine 40, 587–606.Google ScholarPubMed
Covey, TM et al. (2012) PORCN moonlights in a Wnt-independent pathway that regulates cancer cell proliferation. PLoS ONE 7, e34532.CrossRefGoogle Scholar
Fisusi, FA et al. (2019) Drug combinations in breast cancer therapy. Pharmaceutical Nanotechnology 7, 3–23.CrossRefGoogle ScholarPubMed
Qi, F et al. (2015) The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Bioscience Trends 9, 16–34.CrossRefGoogle ScholarPubMed
Mondal, A et al. (2019) Alkaloids for cancer prevention and therapy: current progress and future perspectives. European Journal of Pharmacology 858, 172472.CrossRefGoogle ScholarPubMed
Hu, Z et al. (2022) Current research status of alkaloids against breast cancer. Chinese Journal of Physiology 65, 12–20.Google ScholarPubMed
Lichman, BR (2021) The scaffold-forming steps of plant alkaloid biosynthesis. Natural Product Reports 38, 103–129.CrossRefGoogle ScholarPubMed
Liu, C et al. (2019) Alkaloids from traditional Chinese medicine against hepatocellular carcinoma. Biomedicine & Pharmacotherapy 120, 109543.CrossRefGoogle ScholarPubMed
He, X et al. (2015) Sophora flavescens Ait.: traditional usage, phytochemistry and pharmacology of an important traditional Chinese medicine. Journal of Ethnopharmacology 172, 10–29.CrossRefGoogle ScholarPubMed
Chen, Y (2019) Oxymatrine reverses epithelial-mesenchymal transition in breast cancer cells by depressing αβ integrin/FAK/PI3K/Akt signaling activation. Onco Targets and Therapy 12, 6253–6265.CrossRefGoogle Scholar
Wang, W et al. (2015) Anti-tumor activities of active ingredients in compound Kushen injection. Acta Pharmacologica Sinica 36, 676–679.CrossRefGoogle ScholarPubMed
Garcia, J et al. (2020) Bevacizumab (Avastin(R)) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treatment Reviews 86, 102017.CrossRefGoogle Scholar
Zhang, L et al. (2017) VEGF-A/neuropilin 1 pathway confers cancer stemness via activating Wnt/β-catenin axis in breast cancer cells. Cellular Physiology and Biochemistry 44, 1251–1262.CrossRefGoogle ScholarPubMed
Xie, W et al. (2019) Oxymatrine enhanced anti-tumor effects of bevacizumab against triple-negative breast cancer via abating Wnt/β-catenin signaling pathway. American Journal of Cancer Research 9, 1796–1814.Google ScholarPubMed
Zhang, Y et al. (2011) Oxymatrine diminishes the side population and inhibits the expression of β-catenin in MCF-7 breast cancer cells. Medical Oncology 28(suppl. 1), S99–107.CrossRefGoogle ScholarPubMed
Zheng, J et al. (2016) Spices for prevention and treatment of cancers. Nutrients 8, 495.CrossRefGoogle ScholarPubMed
Lim, JS et al. (2022) Piperine: an anticancer and senostatic drug. Frontiers in Bioscience 27, 137.CrossRefGoogle ScholarPubMed
Barceloux, DG (2009) Pepper and capsaicin (capsicum and piper species). Disease-a-Month 55, 380–390.CrossRefGoogle ScholarPubMed
Rajagopal, C et al. (2018) Targeting oncogenic transcription factors by polyphenols: a novel approach for cancer therapy. Pharmacological Research 130, 273–291.CrossRefGoogle ScholarPubMed
Chapa-Oliver, AM et al. (2016) Capsaicin: from plants to a cancer-suppressing agent. Molecules 21, 931.CrossRefGoogle ScholarPubMed
Fokkens, W et al. (2016) Capsaicin for rhinitis. Current Allergy and Asthma Reports 16, 60.CrossRefGoogle ScholarPubMed
Pramanik, KC et al. (2015) Inhibition of β-catenin signaling suppresses pancreatic tumor growth by disrupting nuclear β-catenin/TCF-1 complex: critical role of STAT-3. Oncotarget 6, 11561–11574.CrossRefGoogle ScholarPubMed
Zhu, M et al. (2020) Capsaicin suppressed activity of prostate cancer stem cells by inhibition of Wnt/β-catenin pathway. Phytotherapy Research 34, 817–824.CrossRefGoogle ScholarPubMed
Wu, D et al. (2020) Capsaicin suppresses breast cancer cell viability by regulating the CDK8/PI3K/Akt/Wnt/β-catenin signaling pathway. Molecular Medicine Reports 22, 4868–4876.CrossRefGoogle ScholarPubMed
Canton-Alvarez, JA (2019) A gift from the Buddhist monastery: the role of Buddhist medical practices in the assimilation of the opium poppy in Chinese medicine during the Song dynasty (960–1279). Medical History 63, 475–493.CrossRefGoogle ScholarPubMed
De Gregori, S et al. (2012) Morphine metabolism, transport and brain disposition. Metabolic Brain Disease 27, 1–5.CrossRefGoogle ScholarPubMed
Gach, K et al. (2011) The role of morphine in regulation of cancer cell growth. Naunyn-Schmiedeberg's Archives of Pharmacology 384, 221–230.CrossRefGoogle ScholarPubMed
Niu, DG et al. (2015) Morphine promotes cancer stem cell properties, contributing to chemoresistance in breast cancer. Oncotarget 6, 3963–3976.CrossRefGoogle ScholarPubMed
Montagna, G et al. (2021) Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer. British Journal of Anaesthesia 126, 367–376.CrossRefGoogle ScholarPubMed
Rolle, J et al. (2021) Jatrorrhizine: a review of its pharmacological effects. Journal of Pharmacy and Pharmacology 73, 709–719.CrossRefGoogle ScholarPubMed
Zhong, F et al. (2021) Jatrorrhizine: a review of sources, pharmacology, pharmacokinetics and toxicity. Frontiers in Pharmacology 12, 783127.CrossRefGoogle ScholarPubMed
Lu, K et al. (2020) Apoptosis activation in thyroid cancer cells by jatrorrhizine-platinum(II) complex via downregulation of PI3K/AKT/mammalian target of rapamycin (mTOR) pathway. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 26, e922518.CrossRefGoogle ScholarPubMed
Sun, Y et al. (2019) Jatrorrhizine inhibits mammary carcinoma cells by targeting TNIK mediated Wnt/β-catenin signalling and epithelial-mesenchymal transition (EMT). Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 63, 153015.CrossRefGoogle ScholarPubMed
Qin, QP et al. (2019) Two telomerase-targeting Pt(ii) complexes of jatrorrhizine and berberine derivatives induce apoptosis in human bladder tumor cells. Dalton Transactions 48, 15247–15254.CrossRefGoogle ScholarPubMed
Wang, P et al. (2019) Jatrorrhizine inhibits colorectal carcinoma proliferation and metastasis through Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition. Drug Design, Development and Therapy 13, 2235–2247.CrossRefGoogle ScholarPubMed
Wang, J et al. (2019) Coptidis rhizoma: a comprehensive review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. Pharmaceutical Biology 57, 193–225.CrossRefGoogle ScholarPubMed
Ortiz, LM et al. (2014) Berberine, an epiphany against cancer. Molecules 19, 12349–12367.CrossRefGoogle ScholarPubMed
Rauf, A et al. (2021) Berberine as a potential anticancer agent: a comprehensive review. Molecules 26, 7368.CrossRefGoogle ScholarPubMed
Li, DD et al. (2020) Berberine: a promising natural isoquinoline alkaloid for the development of hypolipidemic drugs. Current Topics in Medicinal Chemistry 20, 2634–2647.CrossRefGoogle ScholarPubMed
Albring, KF et al. (2013) Berberine acts as a natural inhibitor of Wnt/beta-catenin signaling – identification of more active 13-arylalkyl derivatives. Biofactors 39, 652–662.CrossRefGoogle ScholarPubMed
Dian, L et al. (2022) Berberine alkaloids inhibit the proliferation and metastasis of breast carcinoma cells involving Wnt/beta-catenin signaling and EMT. Phytochemistry 200, 113217.CrossRefGoogle ScholarPubMed
Feng, Y et al. (2018) Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes & Diseases 5, 77–106.CrossRefGoogle ScholarPubMed
Zheng, LP et al. (2022) Characterization of the complete chloroplast genome of Fibraurea recisa Pierre 1885 (Menispermaceae), an important medicinal herb from Yunnan, China. Mitochondrial DNA. Part B, Resources 7, 501–502.CrossRefGoogle ScholarPubMed
Su, CR et al. (2008) Anti-inflammatory activities of furanoditerpenoids and other constituents from Fibraurea tinctoria. Bioorganic & Medicinal Chemistry 16, 9603–9609.CrossRefGoogle ScholarPubMed
Zhang, XJ et al. (2018) Palmatine ameliorated murine colitis by suppressing tryptophan metabolism and regulating gut microbiota. Pharmacological Research 137, 34–46.CrossRefGoogle ScholarPubMed
Zhang, X et al. (2021) Small molecule palmatine targeting musashi-2 in colorectal cancer. Frontiers in Pharmacology 12, 793449.CrossRefGoogle ScholarPubMed
Chen, M et al. (2021) Comprehensive analysis of Huanglian Jiedu decoction: revealing the presence of a self-assembled phytochemical complex in its naturally-occurring precipitate. Journal of Pharmaceutical and Biomedical Analysis 195, 113820.CrossRefGoogle ScholarPubMed
Long, J et al. (2019) Palmatine: a review of its pharmacology, toxicity and pharmacokinetics. Biochimie 162, 176–184.CrossRefGoogle ScholarPubMed
Zhou, X et al. (2016) Chondroprotective effects of palmatine on osteoarthritis in vivo and in vitro: a possible mechanism of inhibiting the Wnt/β-catenin and Hedgehog signaling pathways. International Immunopharmacology 34, 129–138.CrossRefGoogle ScholarPubMed
Grabarska, A et al. (2021) Palmatine, a bioactive protoberberine alkaloid isolated from Berberis cretica, inhibits the growth of human estrogen receptor-positive breast cancer cells and acts synergistically and additively with doxorubicin. Molecules 26, 6253.CrossRefGoogle ScholarPubMed
Eslahi, M et al. (2021) Chitosan and Wnt/beta-catenin signaling pathways in different cancers. Combinatorial Chemistry & High Throughput Screening 24, 1323–1331.CrossRefGoogle ScholarPubMed